It is with great regret that we report the death of a patient in the STEM PD trial. The death was caused by an opportunistic infection which was possibly related to the immunosuppressive treatment the patient was taking. An increased risk of invasive infection is a recognized but uncommon complication of immunosuppression. Despite prophylactic measures and intensive treatment, the patient unfortunately succumbed to the infection.
This event is unrelated to the STEM-PD cell product or the surgical implantation of the cells. The study team completed transplantation of all patients in the STEM-PD trial in October 2024 and will continue to monitor the patients closely.
The STEM-PD Clinical Trial 